Celyad Oncology Statistics

Total Valuation

Celyad Oncology has a market cap or net worth of EUR 21.96 million. The enterprise value is 16.72 million.

Market Cap	21.96M
Enterprise Value	16.72M

Important Dates

The next estimated earnings date is Friday, April 4, 2025.

Earnings Date	Apr 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Celyad Oncology has 41.43 million shares outstanding. The number of shares has increased by 55.53% in one year.

Current Share Class	n/a
Shares Outstanding	41.43M
Shares Change (YoY)	+55.53%
Shares Change (QoQ)	+43.60%
Owned by Insiders (%)	0.53%
Owned by Institutions (%)	0.05%
Float	14.14M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	258.79
PB Ratio	6.73
P/TBV Ratio	6.78
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.16
EV / Sales	232.18
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.63

Financial Position

The company has a current ratio of 3.59, with a Debt / Equity ratio of 0.30.

Current Ratio	3.59
Quick Ratio	3.03
Debt / Equity	0.30
Debt / EBITDA	n/a
Debt / FCF	-0.10
Interest Coverage	-63.78

Financial Efficiency

Return on equity (ROE) is -361.90% and return on invested capital (ROIC) is -167.43%.

Return on Equity (ROE)	-361.90%
Return on Assets (ROA)	-38.87%
Return on Invested Capital (ROIC)	-167.43%
Return on Capital Employed (ROCE)	-74.60%
Revenue Per Employee	4,000
Profits Per Employee	-430,667
Employee Count	19
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +56.13% in the last 52 weeks. The beta is 1.21, so Celyad Oncology's price volatility has been higher than the market average.

Beta (5Y)	1.21
52-Week Price Change	+56.13%
50-Day Moving Average	0.51
200-Day Moving Average	0.43
Relative Strength Index (RSI)	47.45
Average Volume (20 Days)	54,042

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Celyad Oncology had revenue of EUR 72,000 and -7.75 million in losses. Loss per share was -0.22.

Revenue	72,000
Gross Profit	38,000
Operating Income	-7.78M
Pretax Income	-7.82M
Net Income	-7.75M
EBITDA	-7.44M
EBIT	-7.78M
Loss Per Share	-0.22

Full Income Statement

Balance Sheet

The company has 6.23 million in cash and 989,000 in debt, giving a net cash position of 5.24 million or 0.13 per share.

Cash & Cash Equivalents	6.23M
Total Debt	989,000
Net Cash	5.24M
Net Cash Per Share	0.13
Equity (Book Value)	3.27M
Book Value Per Share	0.08
Working Capital	6.25M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -9.70 million and capital expenditures -583,000, giving a free cash flow of -10.29 million.

Operating Cash Flow	-9.70M
Capital Expenditures	-583,000
Free Cash Flow	-10.29M
FCF Per Share	-0.25

Full Cash Flow Statement

Margins

Gross Margin	52.78%
Operating Margin	-10,806.94%
Pretax Margin	-10,854.17%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Celyad Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-55.53%
Shareholder Yield	-55.53%
Earnings Yield	-35.31%
FCF Yield	-46.84%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Celyad Oncology has an Altman Z-Score of -39.85. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-39.85
Piotroski F-Score	n/a